Cipla receives FDA confirmation for generic Revlimid
The Food and Drug Administration has cleared Cipla’s lenalidomide capsules in dosage strengths of 5 mg, 10 mg, 15 mg and 25 mg.
Cipla’s lenalidomide capsules are the generic of Bristol Myers Squibb’s (Celgene) Revlimid.
[Read more: Cipla wins FDA OK for generic Imitrex]
Lenalidomide is an immunomodulatory drug indicated for several hematological malignancies in adults, such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or in combination as a part of first line regimen, maintenance regimen or relapsed settings.
Revlimid had a market value of approximately $ 2.58 billion for the 12 months ending June 2022, according to IQVIA.
[Read more: Cipla gains FDA blessing for generic Somatuline Depot]
The company said that the product will be available for shipping soon.